3 天之前 · Administration of 4F-PCC at a median dose of 26.1 international units (IU)/kg body weight was reported to be efficacious and otherwise uneventful and well tolerated, with no changes in vital signs [33]. After a single infusion, 4 F-PCC demonstrated good hemostatic efficacy in 85% of patients and moderate efficacy in 15% of patients [33]. A ...

4 天之前 · 4F-PCC is a blood product derived from pooled plasma that contains a specific combination of clotting factors and their inhibitors of coagulation that help to stop bleeding by supporting thrombin generation, conventionally promoted by frozen plasma. 4F-PCC contains concentrated clotting factors and does not need to be thawed or matched to a ...

2014年12月6日 · Treatment with 4F-PCC was able to fully and statistically significantly reverse bleeding, achieving average bleeding times of 676 seconds. In parallel, the elevation in PT was reversed to 15.1 seconds.

2024年6月6日 · 人凝血酶原复合物(Prothrombin Complex Concentrate,PCC)：是由灭活的因子Ⅱ、Ⅸ、Ⅹ和不定量的因子Ⅶ构成的一种能促进血液凝固的静脉注射血浆蛋白制剂。 通常根据含有凝血因子Ⅶ的高低，将PCC分为四因子PCC（4F-PCC）和三因子PCC（3F-PCC）。

2015年7月1日 · 数据显示， 4f-pcc 组有 78 例患者（90%）达到有效止血，血浆组 61 例（75%），这一结果表明 4f-pcc 的止血 效果不劣于且优于血浆。治疗后 4f-pcc 组有 48 例（55%）患者 inr 快速降低，血浆组为 8 例（10%），由此可见， 4f-pcc 降低 inr 的 效果优于血浆。

4 天之前 · "Patients randomly assigned to treatment with 4F-PCC needed significantly fewer interventions to stop their bleeding, lost less blood, received fewer blood transfusions and had fewer surgical complications than those who were randomly assigned to be treated with frozen plasma," said principal investigator, Keyvan Karkouti, MD. "The results ...

4 天之前 · The finding that 4F-PCC may serve as a more effective alternative to frozen plasma in controlling surgical bleeding is a game-changer,” said Kenichi Tanaka, M.D., who co-led the clinical trial in the United States. Tanaka is a professor and chair of the Department of Anesthesiology at the University of Oklahoma College of Medicine.

2017年12月7日 · With the approval of four-factor prothrombin complex concentrate (4F-PCC, Kcentra) for the reversal of vitamin K antagonist-associated bleeding in the US, it has become a relatively common practice for 4F-PCC to be used in an 'off-label' fashion to correct coagulopathy caused by direct oral anticoagulants (DOACs) such as anti-Xa inhibitors.

Four-factor prothrombin complex concentrate (4F-PCC) is the term used to describe a pathogen-reduced, lyophilized concentrate that contains therapeutic amounts of at least 4 coagulation factors: Factor II (FII), Factor VII (FVII), Factor IX (FIX), and Factor X …

2013年8月9日 · Prothrombin complex concentrate (PCC) provides an alternative to fresh frozen plasma for reversal of VKA-induced coagulopathy (Table). Originally developed as a source of factor IX for treatment of patients with hemophilia B, 3-factor PCC contains factors II, IX, and X but little or no factor VII.